For how we live.
In 7,186 Korean adults followed up to 20 years, people flagged by fasting glucose, glucose tolerance and HbA1c all at once had a 15.3-fold higher risk of type 2 diabetes than normal controls.
Both raise blood sugar, but for opposite reasons. Type 1 is an autoimmune loss of insulin; type 2 is the body resisting the insulin it makes. Type 2 accounts for 90 to 95 percent of cases.
Insulin resistance usually causes no symptoms you can feel, which is why it is found through blood tests rather than how you seem. The visible clues are subtle — and it rarely travels alone.
There is no single number. Normal depends on which test is used and whether you have fasted — and the cut-offs that define prediabetes and diabetes are lines drawn on a continuous scale.
The honest answer is that early type 2 diabetes usually has no signs you can feel. The classic symptoms arrive late, and damage can be under way years before the diagnosis is made.
US preventive guidelines back a blood-sugar test for adults 35 to 70 who carry extra weight; the main diabetes body would test every adult from 35. The gap is about how wide a net catches enough real disease.
Prediabetes is a high-risk state, not a diagnosis of diabetes. In the trial that defined the field, lifestyle change cut progression by 58 percent — and returning to normal glucose carried a benefit of its own.
Saving starch for the end of a meal reliably blunts the glucose rise afterwards in small trials — but the evidence is short-term, low-certainty, and silent on whether it changes long-term control.
Five-day fasting cycles improve risk markers and one 'biological age' estimate in small trials. No human study has yet shown the diet prevents disease or extends life.
The NAD+ precursors sold to slow ageing reliably raise NAD+ and are well tolerated. What the randomised trials do not show is a benefit to muscle, metabolism or how old you are.
Twenty-one years of cancer follow-up, multimorbidity data to 2021, and a randomised trial in frail older adults. In each, metformin did not beat placebo. Lifestyle change did.
The equation converting A1c to average glucose was built from 507 people. In carriers of sickle cell trait the reading runs about 0.3 percentage points low for the same measured glucose.
A meta-analysis of continuous glucose monitors in people without diabetes found a real effect on blood sugar — but only in those with prediabetes. In healthy users, the evidence for a metabolic benefit was not there.
The headline finding is noninferiority. The more useful finding is what the shared denominator was — and how wide a gap the trial was designed to tolerate.
One proposes a rate-of-change benchmark from 153 non-diabetic wearers. The other put ten young adults through food, exercise and a laboratory stress test to see what actually moves the line.
Across 40 trials, self-guided apps moved panic severity modestly and barely touched fear-related cognitions. Clinician-guided versions moved both — which complicates the scalability pitch.